Wedbush analyst Daniel Ives downgrades DocuSign (NASDAQ:DOCU) from Neutral to Underperform and lowers the price target from $80 to $60.
SVB Leerink Maintains Outperform on Replimune Group, Lowers Price Target to $49
SVB Leerink analyst Jonathan Chang maintains Replimune Group (NASDAQ:REPL) with a Outperform and lowers the price target from $55 to $49.